Latest Healthcare News

Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.

UNITH Ltd reported a record quarterly cash receipt of $1.6 million in Q4 FY25, driven by strategic partnerships and platform innovations. The company is poised for growth with a new website launch and expanded European presence.

333D Limited reported a 12% increase in quarterly cash receipts from digital asset management contracts, maintaining steady cash flow despite slight operating cash usage. The company’s annual contract revenue surpassed $970,000, reflecting growing traction in healthcare digital services.

ECS Botanics reports a 20% quarterly surge in direct-to-consumer sales and a record medicinal cannabis harvest, supported by an expanded loan facility to fuel further growth.

Botanix Pharmaceuticals reports a strong commercial ramp-up for Sofdra™, with net revenue jumping from $0.7 million to $4.3 million in one quarter, supported by a $40 million capital raise and a $30 million debt facility.

Australian Foundation Investment Company Limited (AFIC) reported a $285 million net profit for FY2025, declaring a fully franked 14.5c final dividend plus a 5c special dividend tied to capital gains from portfolio adjustments.

Artrya has launched its AI-powered Salix Coronary Anatomy platform in the U.S. and submitted its Coronary Plaque module for FDA clearance, marking a key step in its commercial expansion. A new five-year contract with Tanner Health signals the start of U.S. revenues.

Proteomics International Laboratories has secured $12 million to fast-track its precision diagnostic tests, including the US launch of PromarkerD for diabetic kidney disease, backed by a new AMA billing code. The company also advances its pipeline with new patents and commercial partnerships.

Global Health Limited reported a robust June quarter with a 65% rise in annual sales and a strategic pivot towards AI-driven efficiencies, aiming for profitability by mid-2026.

Elanor Investors Group announces a $125 million strategic investment from Rockworth Capital Partners to stabilise its balance sheet and fund growth, including the acquisition of Singapore’s Firmus Capital.

Elanor Investors Group announces a $125 million recapitalisation through an expanded alliance with Rockworth Capital Partners, including the acquisition of Singapore’s Firmus Capital and a strategic shift towards Pan-Asian real estate markets.

Radiopharm Theranostics has received FDA clearance to begin a Phase I clinical trial for RV-01, a novel radiopharmaceutical targeting the 4Ig isoform of B7-H3 in solid tumors, marking a significant step forward in cancer treatment innovation.